Total Revenue of $77.7 million, an increase of approximately 15% quarter-over-quarterNet Income of $1.3 millionRecord Adjusted EBITDA of $56.3 million, an increase of over 45% ...
Get the latest on Scholar Rock's regulatory strategy, financial outlook, and apitegromab launch plans for SMA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback